ROCO:7427's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.27 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Great Novel Therapeutics Biotech & Medicals Forward Dividend Yield % Related Terms
ROCO:7427 vs VRTX, REGN, ALNY: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Great Novel Therapeutics Biotech & Medicals Forward Dividend Yield % vs Biotechnology Industry
What does a Forward Dividend Yield % of 0.00% mean?
Great Novel Therapeutics Biotech & Medicals (ROCO:7427) has a Forward Dividend Yield % of 0.00% as of Jul. 04, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Great Novel Therapeutics Biotech & Medicals and its competitors. According to the industry distribution chart, Great Novel Therapeutics Biotech & Medicals ranks #999999 out of 149 companies in the Biotechnology industry.
Is Great Novel Therapeutics Biotech & Medicals' Forward Dividend Yield % too high?
Great Novel Therapeutics Biotech & Medicals' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Great Novel Therapeutics Biotech & Medicals ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Great Novel Therapeutics Biotech & Medicals has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Great Novel Therapeutics Biotech & Medicals' Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Great Novel Therapeutics Biotech & Medicals ranks #999999 out of 149 companies for Forward Dividend Yield %. This places Great Novel Therapeutics Biotech & Medicals in the lower half of its industry. The industry median Forward Dividend Yield % is 1.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.27, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Great Novel Therapeutics Biotech & Medicals and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Great Novel Therapeutics Biotech & Medicals's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Great Novel Therapeutics Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals (ROCO:7427) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$25.63, compared to a current price of NT$39.75 — trading 55.1% above its estimated fair value. The current Forward Dividend Yield % is 0.00%. Great Novel Therapeutics Biotech & Medicals' overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Great Novel Therapeutics Biotech & Medicals (ROCO:7427), the current Forward Dividend Yield % is 0.00% as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Overvalued in 2026?
Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals stock appears to be overvalued.
The current stock price of NT$39.75 is trading 55.1% above its estimated GF Value™ of NT$25.63.
GuruFocus considers Great Novel Therapeutics Biotech & Medicals to be Significantly Overvalued.
Key valuation signals for ROCO:7427:
Forward Dividend Yield %: 0.00%
GF Value™: NT$25.63 vs. price of NT$39.75 (55.1% above fair value)
No single metric tells the full story. See the ROCO:7427 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Great Novel Therapeutics Biotech & Medicals Business Description
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.
52GF Score
Get the complete analysis for ROCO:7427
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7427 has been successfully added to your 